Trilaciclib prior to chemotherapy in patients with metastatic triple-negative breast cancer: final efficacy and subgroup analysis from a randomized phase II study.
Antoinette R TanGail S WrightAnu R ThummalaMichael A DansoLazar PopovicTimothy J PluardHyo S HanŽeljko VojnovićNikola VasevLing MaDonald A RichardsSharon T WilksDušan MilenkovićJie XiaoJessica SorrentinoJanet HortonJoyce O'ShaughnessyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Administering trilaciclib prior to GCb enhanced antitumor efficacy, with significant improvements in OS. Efficacy outcomes in immunologic subgroups and enhancements in T-cell activation suggest these improvements may be mediated via immunologic mechanisms.